FRMS CO., LTD(SZ:300049) EBSCN·2026-03-27 07:07Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [6]. Core Insights - The company achieved a revenue of 1.595 billion yuan in 2025, representing an 18.26% year-on-year growth, while the net profit attributable to shareholders reached 154 million yuan, up 36.02% year-on-year [1][2]. - The company continues to enhance its global presence, with overseas revenue accounting for 66.67% of total revenue in 2025, amounting to 1.064 billion yuan, a 24.59% increase [3]. - Research and development (R&D) investment increased by 11.78% to 111 million yuan in 2025, supporting significant innovation in product offerings [2][3]. Summary by Sections Financial Performance - In Q4 2025, the company reported a revenue of 494 million yuan, a 33.91% increase year-on-year, and a net profit of 42 million yuan, soaring 274.03% year-on-year [1]. - The operating cash flow increased by 58.77% year-on-year, driven by growth in the Echosens and domestic pharmaceutical segments [2]. Cost Structure - The sales expense ratio was 24.46%, down 1.01 percentage points year-on-year, while the management expense ratio slightly increased to 17.86% [2]. - R&D expense ratio decreased to 6.97%, indicating a focus on efficiency in spending [2]. Product and Market Development - The core product, the FibroScan® series, received multiple certifications, including from the EU, FDA, and NMPA, and is included in WHO guidelines for liver disease detection [3]. - The company is expanding its collaboration with global pharmaceutical companies, which is expected to support ongoing growth in international markets [3]. Profit Forecast and Valuation - The net profit forecasts for 2026 and 2027 have been adjusted downwards to 207 million yuan and 275 million yuan, respectively, reflecting increased costs associated with product expansion [3]. - The current stock price corresponds to a price-to-earnings (P/E) ratio of 73 for 2026, 55 for 2027, and 42 for 2028, indicating a premium valuation [3].